New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
11:50 EDTAZN, CGIXCancer Genetics rises after selection by AstraZeneca unit
Shares of Cancer Genetics (CGIX), an early-stage, diagnostic company that focuses on developing and commercializing genomic tests and services focused on improving cancer care, are higher this morning after the company announced a partnership with AstraZeneca (AZN). WHAT'S NEW: AstraZeneca CAMCAR, a division of the pharmaceutical giant that serves Central American and Caribbean countries, has selected Cancer Genetics to provide diagnostic testing based on biomarkers for cancer. CGI will perform complex testing for diagnosis and prognosis of cancer patients in Central America and the Caribbean. Under the terms of the agreement, CGI will be working closely with AZ-CAMCAR on exploring opportunities to expand into additional geographic territories, more cancer categories and into select oncology trials. This partnership will focus on multiple cancer categories beginning with lung cancer, as the Pan American Health Organization, or PAHO, expects cases the number of new cases and deaths from lung cancer to double in Latin America by 2030. WHAT'S NOTABLE: Cancer Genetics Chief Executive Officer Panna Sharma commented, "We believe our ability to provide accurate, state-of-the-art biomarker-based testing was a key factor in AstraZeneca’s decision to partner with us, and serves as a testament to the growing global awareness of the value of our brand. We are committed to positively impacting cancer care globally, and this relationship serves as another major milestone in fulfilling that mission." PRICE ACTION: Cancer Genetics is trading up 38c, or 3.4%, to $11.58 in late-morning trading.
News For CGIX;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
10:00 EDTAZNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Outperform from Market Perform at Cowen... Acadia Realty Trust (AKR) upgraded to Buy from Neutral at Citi... Alliance Resource Partners (ARLP) upgraded to Buy from Hold at Deutsche Bank... ArcBest (ARCB) upgraded to Peer Perform from Underperform at Wolfe Research... AstraZeneca (AZN) upgraded to Buy from Hold at Berenberg... ConAgra (CAG) upgraded to Overweight from Equal Weight at Morgan Stanley... DuPont Fabros (DFT) upgraded to Buy from Neutral at Citi... EastGroup Properties (EGP) upgraded to Buy from Neutral at Citi... Galaxy Entertainment (GXYEY) upgraded to Hold from Sell at Deutsche Bank... GrubHub (GRUB) upgraded to Outperform from Sector Perform at RBC Capital... HealthSouth (HLS) upgraded to Outperform from Market Perform at JMP Securities... IGM Financial (IGIFF) upgraded to Sector Performer from Underperformer at CIBC... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Kimco Realty (KIM) upgraded to Buy from Neutral at Citi... Kosmos (KOS) upgraded to Outperform at BMO Capital... MGM China (MCHVF) upgraded to Hold from Sell at Deutsche Bank... Regal Entertainment (RGC) upgraded to Neutral from Sell at B. Riley... SL Green Realty (SLG) upgraded to Buy from Neutral at Citi... SQM (SQM) upgraded to Buy from Hold at HSBC... Sands China (SCHYY) upgraded to Hold from Sell at Deutsche Bank... Terex (TEX) upgraded to Neutral from Underperform at BofA/Merrill... United Community Banks (UCBI) upgraded to Outperform from Market Perform at Raymond James... Weingarten Realty (WRI) upgraded to Buy from Neutral at Citi... Willis Group (WSH) upgraded to Neutral from Sell at Goldman... Wynn Macau (WYNMF) upgraded to Hold from Sell at Deutsche Bank.
05:30 EDTAZNAstraZeneca upgraded to Buy from Hold at Berenberg
Subscribe for More Information
June 30, 2015
10:19 EDTAZNAstraZeneca, Eolas Therapeutics partner on EORA program for smoking cessation
Eolas Therapeutics said that is has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics grant from the National Institutes of Health for the development of the program from the preclinical stage through phase I clinical trials. The total deal potential is in excess of $145M. This includes upfront, clinical and regulatory milestone payments. Additionally, Eolas is eligible to receive royalties on commercial sales.
07:45 EDTCGIXCancer Genetics awarded multimillion dollar clinical trial
Cancer Genetics announced that it has been awarded a multimillion dollar, clinical trial in hematological cancers by a leading biotech company – the trial is the largest in the company's history of providing clinical trial and genomic services to global biopharma companies. As part of the agreement, CGI will perform all testing, and provide genomic information and monitoring for CLL patients enrolled in multi-arm, randomized, multicenter, global trials. The CLL trials are expected to contribute up to $6.2M in revenue over several years as patients are selected, treated, and monitored using pathway-specific, targeted therapies, and combination therapies.
June 29, 2015
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
June 25, 2015
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
June 24, 2015
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
June 18, 2015
07:36 EDTAZNReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use